title: Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome.
abstract: Eight patients with biopsy-proven primary nephrotic syndrome were included in an open, prospective, two-year study of lovastatin. One patients was withdrawn after 6 months due to an asymptomatic rise in creatinine phosphokinase, which was rapidly reversed after interruption of lovastatin. In the remaining patients, treatment was well-tolerated and produced no side effects. After 2 years of treatment, these 7 patients had decreases in total cholesterol from 446 +/- 165 to 250 +/- 57 mg/dl (p < 0.001), LDL cholesterol from 343 +/- 121 to 174 +/- 49 mg/dl (p < 0.001), Apo B lipoprotein from 162 +/- 60 to 108 +/- 42 mg/dl (p < 0.05), triglycerides from 336 +/- 273 to 182 +/- 71 mg/dl (p < 0.04). There was no change in HDL cholesterol. The LDL/HDL cholesterol and the total/HDL cholesterol ratios fell from 15.0 +/- 12.1 and 19.1 +/- 17.2 mg/dl before the study to 4.4 +/- 1.2 and 6.3 +/- 1.6 mg/dl, respectively, at 2 years. A decrease in proteinuria from 8.6 +/- 4.6 to 5.0 +/- 3.7 g/24 h (p < 0.02) was noted in 4 patients on concomitant ACE inhibitor therapy. Renal function remained stable in all patients throughout the study, except for one whose moderate impairment progressed to end-stage renal failure requiring dialysis 3 months poststudy. We conclude that long-term lovastatin in patients with primary nephrotic syndrome is an effective and generally safe treatment for accompanying dyslipidemia.
authors.affiliation: Department of Nephrology, Hospital Universitario Santa Maria, Lisboa, Portugal.
authors.forename: M M
authors.initials: MM
authors.lastname: Prata
authors.forename: A C
authors.initials: AC
authors.lastname: Nogueira
authors.forename: J R
authors.initials: JR
authors.lastname: Pinto
authors.forename: A M
authors.initials: AM
authors.lastname: Correia
authors.forename: O
authors.initials: O
authors.lastname: Vicente
authors.forename: M C
authors.initials: MC
authors.lastname: Rodrigues
authors.forename: M J
authors.initials: MJ
authors.lastname: Miguel
mesh_terms: D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology; D008074:Lipoproteins / Q000097:blood*; D008134:Long-Term Care; D008148:Lovastatin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D010342:Patient Acceptance of Health Care; D011446:Prospective Studies; D011507:Proteinuria / Q000652:urine; D014280:Triglycerides / Q000097:blood
chemical_list: D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol; D008148:Lovastatin